U.S. Hematology Diagnostics Market Size, Share & Trends Analysis Report By Product (Instrument, Consumable), By Test Type, By End-use (Hospital, Diagnostic Lab), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Hematology Diagnostics Market Growth & Trends
The U.S. hematology diagnostics market size is anticipated to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer is one of the primary factors contributing to the market growth. According to the American Cancer Society, Inc., in 2021, over 1.9 million new cancer cases were diagnosed, and over 600,000 people died from cancer in the same year. Hence, the demand for cancer diagnostics is expected to grow.
In addition, technological advancements have revolutionized blood testing systems, making them simpler and less painful for patients. The future of hematology diagnostics looks promising owing to increased investments in research and development focused on blood-related diseases. With rising healthcare expenditure and a growing focus on improving diagnostic capabilities, the market for hematology diagnostics is expected to experience significant growth in the forecast period.
The rising prevalence of blood-related conditions is a significant driver behind the growth of the hematology diagnostics market in the U.S. Expansion in this market is predominantly propelled by emerging research endeavors exploring the effectiveness of hematology diagnostics in the early identification of different types of cancers. According to estimates from the Leukemia & Lymphoma Society, in 2023, about 59,610 people are expected to be diagnosed with leukemia, and about 1,958,310 new cases of leukemia were reported in the U.S.
U.S. Hematology Diagnostics Market Report Highlights
U.S. Hematology Diagnostics Market Growth & Trends
The U.S. hematology diagnostics market size is anticipated to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer is one of the primary factors contributing to the market growth. According to the American Cancer Society, Inc., in 2021, over 1.9 million new cancer cases were diagnosed, and over 600,000 people died from cancer in the same year. Hence, the demand for cancer diagnostics is expected to grow.
In addition, technological advancements have revolutionized blood testing systems, making them simpler and less painful for patients. The future of hematology diagnostics looks promising owing to increased investments in research and development focused on blood-related diseases. With rising healthcare expenditure and a growing focus on improving diagnostic capabilities, the market for hematology diagnostics is expected to experience significant growth in the forecast period.
The rising prevalence of blood-related conditions is a significant driver behind the growth of the hematology diagnostics market in the U.S. Expansion in this market is predominantly propelled by emerging research endeavors exploring the effectiveness of hematology diagnostics in the early identification of different types of cancers. According to estimates from the Leukemia & Lymphoma Society, in 2023, about 59,610 people are expected to be diagnosed with leukemia, and about 1,958,310 new cases of leukemia were reported in the U.S.
U.S. Hematology Diagnostics Market Report Highlights
- Based on product, consumables dominated the market with a share of around 65% in 2023 and are expected to register the fastest CAGR during the forecast period. Hematology diagnostic consumables are indeed crucial components in the daily functions of diagnostic labs and healthcare facilities. These consumables are integral to conducting various hematology tests and procedures essential for patient care
- Based on test type, the white blood cell (WBC) test segment accounted for the largest market share in 2023 and is expected to register the fastest CAGR during the forecast period. The demand for White Blood Cell (WBC) testing in the market is primarily fueled by the need for precise and prompt evaluation of white and differential counts. This testing is a standard practice in clinical settings as it plays a crucial role in diagnosing and monitoring a wide range of medical conditions in the U.S. market
- Based on end-use, the hospitals segment dominated the market in 2023. On the other hand, the diagnostic labs segment is projected to grow at the fastest CAGR over the forecast period. Blood testing laboratories play a vital role in healthcare by providing accurate and reliable results for diagnosing and managing blood disorders, infections, and other health conditions. They help healthcare providers make informed decisions about patient care based on the test results. All factors would drive the market segment's growth
- In 2021, Illumina launched the TruSight Hematology Panel, a next-generation sequencing (NGS) panel designed to detect hematological disorders. This innovative solution enables comprehensive genetic analysis, providing valuable insights for diagnosis and treatment
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Instrument
1.2.3. Test Type
1.2.4. End-use
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Instrument
2.2.3. Test Type
2.2.4. End-use
2.3. Competitive Insights
CHAPTER 3. U.S. HEMATOLOGY DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Hematology Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. HEMATOLOGY DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Hematology Diagnostics Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Instruments
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Hematology Analyzers
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2.2. Clinical Laboratory Testing Hematology Analyzers
4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2.2.2. Point-Of-Care Testing Hematology Analyzers
4.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Flow Cytometers
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Slide Stainers/Markers
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Consumables
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Reagents
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Stains
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Controls and Calibrators
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. U.S. HEMATOLOGY DIAGNOSTICS MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
5.1. Test Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Hematology Diagnostics Market by Test Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. White Blood Cells (WBC) Test
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Red Blood Cells (RBC) Test
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hemoglobin Test
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Hematocrit Test
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Platelet Function
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. U.S. HEMATOLOGY DIAGNOSTICS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Hematology Diagnostics Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Diagnostic Labs
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. U.S. HEMATOLOGY DIAGNOSTICS MARKET: REGION ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share, 2023 & 2030
7.2. U.S. Hematology Diagnostics Market by Region Outlook
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.3.1. West
7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Midwest
7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Northeast
7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.4. Southwest
7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.5. Southeast
7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Abbott
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Beckman Coulter
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Sysmex Corporation
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Horiba
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Bio-Rad Laboratories
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Siemens Healthcare
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. F. Hoffmann-La Roche Ltd.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Mindray
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Nihon Kohden
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. EKF Diagnostics
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Instrument
1.2.3. Test Type
1.2.4. End-use
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Instrument
2.2.3. Test Type
2.2.4. End-use
2.3. Competitive Insights
CHAPTER 3. U.S. HEMATOLOGY DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Hematology Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. HEMATOLOGY DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Hematology Diagnostics Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Instruments
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Hematology Analyzers
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2.2. Clinical Laboratory Testing Hematology Analyzers
4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2.2.2. Point-Of-Care Testing Hematology Analyzers
4.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Flow Cytometers
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Slide Stainers/Markers
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Consumables
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Reagents
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Stains
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Controls and Calibrators
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. U.S. HEMATOLOGY DIAGNOSTICS MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
5.1. Test Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Hematology Diagnostics Market by Test Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. White Blood Cells (WBC) Test
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Red Blood Cells (RBC) Test
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hemoglobin Test
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Hematocrit Test
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Platelet Function
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. U.S. HEMATOLOGY DIAGNOSTICS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Hematology Diagnostics Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Diagnostic Labs
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. U.S. HEMATOLOGY DIAGNOSTICS MARKET: REGION ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share, 2023 & 2030
7.2. U.S. Hematology Diagnostics Market by Region Outlook
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.3.1. West
7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Midwest
7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Northeast
7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.4. Southwest
7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.5. Southeast
7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Abbott
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Beckman Coulter
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Sysmex Corporation
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Horiba
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Bio-Rad Laboratories
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Siemens Healthcare
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. F. Hoffmann-La Roche Ltd.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Mindray
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Nihon Kohden
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. EKF Diagnostics
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 U.S. hematology diagnostics market, by product, 2018 - 2030 (USD Million)
Table 3 U.S. hematology diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 4 U.S. hematology diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 5 U.S. hematology diagnostics market, by region, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 U.S. hematology diagnostics market, by product, 2018 - 2030 (USD Million)
Table 3 U.S. hematology diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 4 U.S. hematology diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 5 U.S. hematology diagnostics market, by region, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. hematology diagnostics market outlook
Fig. 9 Hematology diagnostics competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. hematology diagnostics market driver impact
Fig. 14 U.S. hematology diagnostics market restraint impact
Fig. 15 U.S. hematology diagnostics market: Product movement analysis
Fig. 16 U.S. hematology diagnostics market: Product outlook and key takeaways
Fig. 17 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Consumables estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 U.S. hematology diagnostics market: Test type movement Analysis
Fig. 20 U.S. hematology diagnostics market: Test type outlook and key takeaways
Fig. 21 White blood cells (WBC) test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Red blood cells (RBC) test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Hemoglobin test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Hematocrit test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Platelet function market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 U.S. hematology diagnostics market: End-use movement Analysis
Fig. 27 U.S. hematology diagnostics market: End-use outlook and key takeaways
Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Diagnostic labs test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 U.S. hematology diagnostics market: Regional movement analysis
Fig. 32 U.S. hematology diagnostics market: Regional outlook and key takeaways
Fig. 33 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. hematology diagnostics market outlook
Fig. 9 Hematology diagnostics competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. hematology diagnostics market driver impact
Fig. 14 U.S. hematology diagnostics market restraint impact
Fig. 15 U.S. hematology diagnostics market: Product movement analysis
Fig. 16 U.S. hematology diagnostics market: Product outlook and key takeaways
Fig. 17 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Consumables estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 U.S. hematology diagnostics market: Test type movement Analysis
Fig. 20 U.S. hematology diagnostics market: Test type outlook and key takeaways
Fig. 21 White blood cells (WBC) test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Red blood cells (RBC) test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Hemoglobin test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Hematocrit test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Platelet function market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 U.S. hematology diagnostics market: End-use movement Analysis
Fig. 27 U.S. hematology diagnostics market: End-use outlook and key takeaways
Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Diagnostic labs test market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 U.S. hematology diagnostics market: Regional movement analysis
Fig. 32 U.S. hematology diagnostics market: Regional outlook and key takeaways
Fig. 33 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
